EXEL - Exelixis, Inc.
21.27 0.00 (0.00%)
After hours: 5:05PM EDT
| Previous Close | 22.13 |
| Open | 22.14 |
| Bid | 21.24 x 3000 |
| Ask | 21.25 x 900 |
| Day's Range | 21.22 - 22.25 |
| 52 Week Range | 13.42 - 25.31 |
| Volume | 2,081,042 |
| Avg. Volume | 2,918,329 |
| Market Cap | 6.419B |
| Beta (3Y Monthly) | 1.68 |
| PE Ratio (TTM) | 10.23 |
| EPS (TTM) | 2.08 |
| Earnings Date | Jul 31, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.08 |
- Simply Wall St.•yesterday
Exelixis (NASDAQ:EXEL) Shareholders Have Enjoyed A Whopping 474% Share Price Gain
For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock...
- Zacks•yesterday
EXEL or ILMN: Which Is the Better Value Stock Right Now?
EXEL vs. ILMN: Which Stock Is the Better Value Option?
- Business Wire•2 days ago
Exelixis to Release Second Quarter 2019 Financial Results on Wednesday, July 31, 2019
– Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT –
- Zacks•2 days ago
Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study
Key highlights of the past week include collaborations and other pipeline updates.
- Zacks•3 days ago
Exelixis Adds & Expands Cohorts in Cabometyx-Tecentriq Study
Exelixis (EXEL) adds four cohorts and expands two cohorts in the early-stage study evaluating lead drug, Cabometyx, in combination with Tecentriq.
- Business Wire•4 days ago
Exelixis Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Patients With Advanced Solid Tumors
– Original metastatic castration-resistant prostate cancer and immunotherapy-refractory non-small cell lung cancer cohorts expanded to 80 subjects –
- GuruFocus.com•15 days ago
Exelixis Inc (EXEL) President and CEO Michael Morrissey Sold $730,183 of Shares
President and CEO of Exelixis Inc (NASDAQ:EXEL) Michael Morrissey sold 34,721 shares of EXEL on 07/03/2019 at an average price of $21.03 a share.
- Motley Fool•19 days ago
Is Exelixis a Buy?
This biotech might be a one-trick pony for now. But it's got a great horse to ride.
- Motley Fool•20 days ago
3 Cancer-Treatment Stocks to Buy
These three businesses are a great way for investors to support the war on cancer.
- American City Business Journals•25 days ago
Health Care Digest: How California's stem cell institute may help find glaucoma cure; a stealthy biotech with $100M; and more
The future of California's stem cell research funding agency is in doubt, but its impact goes far beyond the billions of dollars it has doled out to researchers, says the Glaucoma Research Foundation.
- Motley Fool•25 days ago
Read This Before You Buy Any New Cancer Drug Stocks
Around $36 billion worth of biopharma acquisitions over the past few years suggests smaller might be better.
- Motley Fool•28 days ago
Oh, By the Way, This Clinical Trial Didn't Work
Sometimes, you hear the bad news from a friend of a friend.
- Market Realist•28 days ago
Exelixis Stock Is Up despite Disappointing Clinical Trial Results
While Exelixis was down 5.9% in after-hours trading after the announcement of disappointing clinical trial results, the stock recovered the losses and closed at $21.14 yesterday, 0.81% higher than its previous close. Based on this price performance, it seems that shareholders had already priced in the trial's failure.
- Investor's Business Daily•28 days ago
Dow Jones Futures: Canopy Growth, PayPal, Lululemon, Exelixis Active
Stock futures: Canopy Growth reported a wider-than-expected Q4 loss. PayPal, Lululemon Athletica and Exelixis moved overnight on news.
- Benzinga•28 days ago
The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 20) Abbott Laboratories (NYSE: ABT ) ANI Pharmaceuticals ...
- Insider Monkey•29 days ago
Here’s What Hedge Funds Think About Exelixis, Inc. (EXEL)
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the first […]
- TheStreet.com•last month
2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land
"Merger Monday" finally lived up to its billing this week in Biotech Land. announced just before the opening bell Monday that it was acquiring oncology concern Array Biopharma Inc. Pfizer paid a buyout premium of more than 60% to purchase Array.
- Markit•last month
See what the IHS Markit Score report has to say about Exelixis Inc.
Exelixis Inc NASDAQ/NGS:EXELView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for EXEL with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding EXEL totaled $321 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- MoneyShow•last month
Exelixis Bets on Breakthroughs in Oncology
Based in San Francisco, Exelixis (EXEL) is a drug company that is dedicated to the discovery, development and commercialization of new medicines for cancer treatment, asserts Mark Skousen, growth stock expert and editor of Five-Star Trader.
- Motley Fool•last month
Top 5 Stocks in the Fight Against Cancer
These stocks are leading the way in their respective areas in battling cancer.
- Zacks•2 months ago
Why Is Exelixis (EXEL) Down 1% Since Last Earnings Report?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.•2 months ago
Is Exelixis, Inc.'s (NASDAQ:EXEL) CEO Being Overpaid?
Michael Morrissey became the CEO of Exelixis, Inc. (NASDAQ:EXEL) in 2010. This analysis aims first to contrast CEO...
- Business Wire•2 months ago
Exelixis Announces Webcasts of Investor Conference Presentations in June 2019
̶ Presentations to be webcast on www.exelixis.com ̶
